​
​

Recursion Pharmaceuticals (RXRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Recursion Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$44.58M

Latest Revenue (Q)

$14.42M

Main Segment (Y)

License and Service

Recursion Pharmaceuticals Revenue by Period

Recursion Pharmaceuticals Revenue by Year

DateRevenueChange
2023-12-31$44.58M12.33%
2022-12-31$39.68M296.81%
2021-12-31$10.00M193.00%
2020-12-31$3.41M99.47%
2019-12-31$1.71M-

Recursion Pharmaceuticals generated $44.58M in revenue during NA 2023, up 12.33% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Recursion Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$14.42M4.52%
2024-03-31$13.79M26.66%
2023-12-31$10.89M7.81%
2023-09-30$10.10M-8.30%
2023-06-30$11.02M-9.21%
2023-03-31$12.13M-11.28%
2022-12-31$13.68M4.77%
2022-09-30$13.05M70.56%
2022-06-30$7.65M44.42%
2022-03-31$5.30M111.96%
2021-12-31$2.50M-
2021-09-30$2.50M-
2021-06-30$2.50M-
2021-03-31$2.50M-2.00%
2020-12-31$2.55M195.94%
2020-09-30$862.00K363.44%
2020-06-30$186.00K210.00%
2020-03-31$60.00K-

Recursion Pharmaceuticals generated $14.42M in revenue during Q2 2024, up 4.52% compared to the previous quarter, and up 118.81% compared to the same period a year ago.

Recursion Pharmaceuticals Revenue Breakdown

Recursion Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 23Dec 22Dec 21
Grant$699.00K$162.00K$178.00K
License and Service$43.88M$39.68M$10.00M

Recursion Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 23: License and Service (98.43%), and Grant (1.57%).

Quarterly Revenue by Product

Product/ServiceSep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
License and Service$26.08M$13.49M$10.62M$10.10M$11.02M$12.13M$13.68M$13.05M$7.65M$5.30M$2.50M$2.50M$2.50M$2.50M
Grant-$303.00K$267.00K$431.00K$1.00K--$107.00K$21.00K$34.00K$33.00K$34.00K$49.00K$62.00K

Recursion Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Sep 24: License and Service (100.00%).

Recursion Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
RXRXRecursion Pharmaceuticals$44.58M$14.42M
VECTVectivBio$27.34M$676.00K
RLAYRelay Therapeutics$25.55M-
AFMDAffimed$8.28M$155.00K
ABSIAbsci$5.72M$898.00K
CWBRCohBar--
XFORX4 Pharmaceuticals-$560.00K
AVROAVROBIO--
CNSPCNS Pharmaceuticals--
DAWNDay One Biopharmaceuticals-$20.07M
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
SANASana Bio--
OCEAOcean Biomedical--
IMMXImmix Biopharma--
HEPAHepion Pharmaceuticals--
ENVBEnveric Biosciences--
EFTReFFECTOR Therapeutics--

RXRX Revenue FAQ

What is Recursion Pharmaceuticals’s yearly revenue?

Recursion Pharmaceuticals's yearly revenue for 2023 was $44.58M, representing an increase of 12.33% compared to 2022. The company's yearly revenue for 2022 was $39.68M, representing an increase of 296.81% compared to 2021. RXRX's yearly revenue for 2021 was $10M, representing an increase of 193.00% compared to 2020.

What is Recursion Pharmaceuticals’s quarterly revenue?

Recursion Pharmaceuticals's quarterly revenue for Q2 2024 was $14.42M, a 4.52% increase from the previous quarter (Q1 2024), and a 30.87% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $13.79M, a 26.66% increase from the previous quarter (Q4 2023), and a 13.68% increase year-over-year (Q1 2023). RXRX's quarterly revenue for Q4 2023 was $10.89M, a 7.81% increase from the previous quarter (Q3 2023), and a -20.36% decrease year-over-year (Q4 2022).

What is Recursion Pharmaceuticals’s revenue growth rate?

Recursion Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was 345.75%, and for the last 5 years (2019-2023) was 2505.20%.

What are Recursion Pharmaceuticals’s revenue streams?

Recursion Pharmaceuticals's revenue streams in c 23 are Grant, and License and Service. Grant generated $699K in revenue, accounting 1.57% of the company's total revenue, up 331.48% year-over-year. License and Service generated $43.88M in revenue, accounting 98.43% of the company's total revenue, up 10.57% year-over-year.

What is Recursion Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Recursion Pharmaceuticals was License and Service. This segment made a revenue of $43.88M, representing 98.43% of the company's total revenue.